Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-19
2000-10-10
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514307, 5142352, 514339, 544144, 546200, 546201, 546164, 546165, 546172, 546173, 546175, 548455, 548460, A61K 3140, C07D20904
Patent
active
061302384
ABSTRACT:
The present invention relates to novel 3-(cyclohexanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
REFERENCES:
patent: Re36256 (1999-07-01), Spada et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
Akbasak and Sunar-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," J. Neurol. Sci. 111:119-133 (1992).
Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b] thiazolylmethylene)-2-indolinones," Eur. J. Med. Chem. 32:919-924 (1997).
Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," J. Clin. Invest. 84:1418-1423 (1989).
Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" Cancer Research 55:249-252 (1995).
Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," FASEB J. 6:3403-3409 (1992).
Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993).
Bonner et al., "Structure and Biological Activity of Human Homologs of the raf/mil Oncogene," Molecular and Cellular Biology 5:1400-1407 (1985).
Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," Molecular and Cellular Biology 14:4588-4595 (1994).
Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 15:61-69 (1988).
Dickson et al., "Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer," Cancer Treatment Res. 61:249-273 (1992).
Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," Cell 69:413-423 (1992).
Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product," Cancer Research 50:1550-1558 (1990).
Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," Kidney International 43:S47-S54 (1993).
Goldring and Goldring, "Cytokines and Cell Growth Control," Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991).
Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994).
Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).
Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993).
Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Exp. Cell Research 199:56-62 (1992).
Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," Science 252:668-674 (1991).
Komada et al., "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," Oncogene 8:2381-2390 (1993).
Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," J. Clin. Invest. 90:1352-1360 (1992).
Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity.sup.1," J. Immunol. Methods 64:313-320 (1983).
Kumabe et al., "Amplification of .alpha.-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," Oncogene 7:627-633 (1992).
Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," Journal of Cell Biology 118:1057-1070 (1992).
Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," Cancer Research 50:2511-2517 (1990).
Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," Experimental Therapeutics--Proceedings of the American Association for Cancer Research 35:381 at abstract No. 2268 (Mar. 1994).
Morrison et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," Proc. Natl. Acad. Sci. USA 85:8855-8859 (1988).
Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Methods 65:55-63 (1983).
Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P 7(6):334-339 (1994).
Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to `Nude` Mice," Acta path. microbiol. scand. 77:758-760 (1969).
Sandberg-Nordqvist et al., "Characerization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," Cancer Research 53:2475-2478 (1993).
Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," Neuron 9:383-391 (1992).
Slamon et al., "Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer," Science 244:707-712 (1989).
Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," Cell 72:767-778 (1993).
Songyang et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," Molecular and Cellular Biology 14:2777-2785 (1994).
Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," Nature Biotech 14:600-605 (1996).
Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src,"EMBO J. 12:2625-2634 (1993).
Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," Mol. Bio. Cell 4:358A at abstract No. 2076 (1993).
Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," AMPIS 100:713-719 (1992).
Tuzi et al., "Expression of growth factor receptors in human brain tumours," Br. J. Cancer 63:227-233 (1991).
Voller et al., "Ch. 45--Enzyme-Linked Immunosorbent Assay," in Manual of Clinical Immunology, 2.sup.nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980).
Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," J. Cellular Physiology 152:448-457 (1992).
McMahon Gerald
Sun Li
Tang Peng Cho
Dolan John F.
Richter Johann
Sugen Inc.
LandOfFree
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine ki does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine ki, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine ki will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257279